Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis

Sjoquist, Katrin Marie; Burmeister, Bryan; Smithers, B. Mark; Zalcberg, John; Simes, R. J.; Barbour, Andrew P.; Gebski, Val

doi:10.1016/s1470-2045(11)70142-5

Cited by 1,497 publications

(1,135 citation statements)

References 41 publications

Supporting

Mentioning

1,069

Contrasting

Unclassified

Order By: Relevance

“…Esophageal squamous cell carcinoma (ESCC) is one of the most common pathologic types in EC (about 90%) (Stoner et al, 2001;Enzinger et al, 2003). Although great improvements have been made in the diagnosis, surgical treatment, chemotherapy and radiotherapy of esophageal cancer, the overall survival rate of esophageal cancer remains poor, with a 5-year survival of 15-34% (Allum et al, 2009;Sjoquist et al, 2011;Siegel et al, 2012;Xu et al, 2012). Therefore, it is extremely necessary to investigate the molecular mechanisms of the development of EC.…”

Section: Introductionmentioning

confidence: 99%

MSP58 Knockdown Inhibits the Proliferation of Esophageal Squamous Cell Carcinoma in Vitro and in Vivo

Zheng²,

Zhang³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Esophageal carcinoma (EC) is one of the most aggressive cancers with a poor prognosis. Understanding the molecular mechanisms underlying esophageal cancer progression is a high priority for improved EC diagnosis and prognosis. Recently, MSP58 was shown to behave as an oncogene in colorectal carcinomas and gliomas. However, little is known about its function in esophageal carcinomas. We therefore examined the effects of MSP58 knockdown on the growth of esophageal squamous cell carcinoma (ESCC) cells in vitro and in vivo in order to gain a better understanding of its potential as a tumor therapeutic target. We employed lentiviral-mediated small hairpin RNA (shRNA) to knock down the expression of MSP58 in the ESCC cell lines Eca-109 and EC9706 and demonstrated inhibition of ESCC cell proliferation and colony formation in vitro. Furthermore, flow cytometry and western blot analyses revealed that MSP58 depletion induced cell cycle arrest by regulating the expression of P21, CDK4 and cyclin D1. Notably, the downregulation of MSP58 significantly inhibited the growth of ESCC xenografts in nude mice. Our results suggest that MSP58 may play an important role in ESCC progression.

show abstract

Section: Introductionmentioning

confidence: 99%

MSP58 Knockdown Inhibits the Proliferation of Esophageal Squamous Cell Carcinoma in Vitro and in Vivo

Zheng²,

Zhang³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…The standard of care for locally advanced AEG II in Europe is perioperative chemotherapy [18,19] or neoadjuvant chemoradiotherapy [20][21][22]. Both treatment regimens have been shown to improve prognosis in comparison to surgery alone.…”

mentioning

confidence: 99%

Surgical strategies in true adenocarcinoma of the esophagogastric junction (AEG II): thoracoabdominal or abdominal approach?

et al. 2017

View full text Add to dashboard Cite

“…CROSS trial revealed pCR rate of 29 % and a low inhospital mortality of 4 %, however increased overall survival, especially in squamous cell carcinoma [12]. Sjoquist et al, in their metaanalysis revealed absolute benefit in overall survival of 2 years in both squamous and adenocarcinoma and similar 30 day perioperative mortality [10].…”

Section: Discussionmentioning

confidence: 98%

“…However the randomized controlled trial by Walsh et al did show improvement in median survival with multimodality treatment [8,9]. The most recent meta-analysis did suggest overall survival benefit with preoperative chemoradiation compared to preoperative chemotherapy across all patient groups (squamous and adenocarcinoma [10].…”

Section: Introductionmentioning

confidence: 99%

Radical Esophagectomy After Neoadjuvant Chemoradiation: Single Institutional Experience from Tertiary Cancer Centre in India

Goel

Shah

Selvakumar

et al. 2015

Indian J Surg Oncol

View full text Add to dashboard Cite

Although preoperative chemoradiation has shown to improve surgical outcomes in both loco-regional control and long term survival; it has still not become the standard of care in many centers. There is reluctance in accepting preoperative chemoradiation primarily due to fear of increased perioperative morbidity/mortality or non-availability of infrastructure and expertise. We present a retrospective analysis of our results of radical esophagectomy after neoadjuvant chemoradiation. All patients who underwent Radical Esophagectomy from January 2009 to December 2013 by a single surgical team at our institute were included in the series (n=118). Patients undergoing surgery after chemo-radiation (group A= 66) were compared with those under going upfront surgery (group B=52) in terms of patient variables (age, sex, comorbidities, tumor location, staging, histology) and postoperative surgical outcomes and complications using Chi square test. Overall and disease free survival was analyzed using Kaplan Meir curve. There was no difference in duration of surgery, postoperative stay and overall morbidity and mortality in both groups. Although group A patients had more of advanced cases clinically, but histopathology showed complete pathological response (pCR) in nearly 40 % patients and negative nodes (pN0) in 62.5 % patients. OS and DFS showed a trend towards better survival with preoperative chemoradiation. We conclude that radical esophagectomy after preoperative chemoradiation is feasible and safe in developing countries. Moreover pathological complete response correlates well with improved survival. Randomized control trials may be required to further substantiate the results.

show abstract

Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis

Cited by 1,497 publications

References 41 publications

MSP58 Knockdown Inhibits the Proliferation of Esophageal Squamous Cell Carcinoma in Vitro and in Vivo

MSP58 Knockdown Inhibits the Proliferation of Esophageal Squamous Cell Carcinoma in Vitro and in Vivo

Surgical strategies in true adenocarcinoma of the esophagogastric junction (AEG II): thoracoabdominal or abdominal approach?

Radical Esophagectomy After Neoadjuvant Chemoradiation: Single Institutional Experience from Tertiary Cancer Centre in India

Contact Info

Product

Resources

About